About the Company
Pacific Biosciences of California, Inc. (aka PacBio) is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.
Sector
Industrial Applications and Services
Industry
Laboratory Analytical Instruments
Employees
699
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $PACB News
JP Morgan Downgrades Pacific Biosciences of California (PACB)
Fintel reports that on April 22, 2024, JP Morgan downgraded their outlook for Pacific Biosciences of California ...
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 18%
Market forces rained on the parade of Pacific Biosciences of California, Inc. ( NASDAQ:PACB ) shareholders today, ...
Pacific Biosciences of California Inc (PACB) vs. Its Peers: A Comparison
Smart investors will not be hesitating on this one! The stock price of Pacific Biosciences of California Inc (NASDAQ: PACB) has dropped by -6.21 compared to previous close of 3.38. Despite this, the ...
Here's Why Pacific Biosciences (PACB) is Poised for a Turnaround After Losing -63.44% in 4 Weeks
Pacific Biosciences (PACB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts ...
Pacific Biosciences of California (PACB) Price Target Decreased by 18.15% to 9.01
The average one-year price target for Pacific Biosciences of California (NasdaqGS:PACB) has been revised to 9.01 / share.
PacBio falls after issuing guidance below expectations
PacBio (PACB) fell ~19% Tuesday pre-market after the healthcare company expects to report Q1 revenue of $38.8M, roughly flat from $38.9M in the prior-year period.
Pacific Biosciences of California, Inc.: PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million Q1 2024 Earnings Conference Call Scheduled for May 9, 2024 MENLO PARK, Calif., April 16, 2024 /PRNewswire/ - PacBio ...
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
The Transplant Company™ – a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value diagnostic solutions for transplant ...
Analysts Offer Insights on Healthcare Companies: Cyclo Therapeutics (CYTH), CytomX Therapeutics (CTMX) and Pacific Biosciences (PACB)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cyclo Therapeutics (CYTH – Research Report), ...
Why INVO Bioscience Shares Are Trading Higher By Around 73%; Here Are 20 Stocks Moving Premarket
Shares of INVO Bioscience, Inc. (NASDAQ: INVO) rose sharply in today’s pre-market trading after reporting fourth-quarter ...
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Skillsoft Corp. (NASDAQ: SKIL) fell sharply during Tuesday’s session after the company reported mixed ...
Fed plan to rebuild Pacific sardine population was insufficient, California judge finds
A plan by federal agencies to rebuild the sardine population in the Pacific was not properly implemented and failed to ...
Loading the latest forecasts...